A Novel Combination of CYP51A Mutations Confers Pan-Azole Resistance in Aspergillus fumigatus-Reference-Cited by-同舟云学术

A Novel Combination of CYP51A Mutations Confers Pan-Azole Resistance in Aspergillus fumigatus

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Macedo Daiana¹²,Brito Devoto Tomás³^ORCID,Pola Santiago⁴,Finquelievich Jorge L.⁴,Cuestas María L.³,Garcia-Effron Guillermo¹²^ORCID

Affiliation:

1. Laboratorio de Micología y Diagnóstico Molecular, Cátedra de Parasitología y Micología, Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina

2. Consejo Nacional de Investigaciones Científicas y Tecnológicas, Santa Fe, Argentina

3. Universidad de Buenos Aires, CONICET, Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM), Buenos Aires, Argentina

4. Universidad de Buenos Aires, Departamento de Microbiología, Centro de Micología, Buenos Aires, Argentina

Abstract

The treatment of invasive and chronic aspergillosis involves triazole drugs. Its intensive use has resulted in the selection of resistant isolates, and at present, azole resistance in Aspergillus fumigatus is considered an emerging threat to public health worldwide. The aim of this work is to uncover the molecular mechanism implicated in the azole resistance phenotype of three Aspergillus fumigatus clinical strains isolated from an Argentinian cystic fibrosis patient under long-term triazole treatment.

Funder

Ministerio de Ciencia, Tecnología e Innovación Productiva

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02501-19

Reference34 articles.

1. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center

2. Molecular epidemiology of Aspergillus collected from cystic fibrosis patients

3. Aspergillus infections in cystic fibrosis